These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical strategy for the development of angiogenesis inhibitors. Carter SK Oncologist; 2000; 5 Suppl 1():51-4. PubMed ID: 10804092 [TBL] [Abstract][Full Text] [Related]
13. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology? Gambacorti C Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608 [No Abstract] [Full Text] [Related]
14. Recent advances in the management of colorectal cancer. Van Cutsem E; Dicato M; Wils J Eur J Cancer; 2001 Dec; 37(18):2302-9. PubMed ID: 11720822 [No Abstract] [Full Text] [Related]
15. The rational basis of using novel targeted biological agents in non-small cell lung cancer. Ciardiello F Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813 [No Abstract] [Full Text] [Related]
16. Cancer treatment. New drugs, new hope. Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447 [No Abstract] [Full Text] [Related]
18. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC. Van Zandwijk N; Baas P Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815 [No Abstract] [Full Text] [Related]
19. The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). Owonikoko TK; Ramalingam S Curr Treat Options Oncol; 2008 Dec; 9(4-6):313-25. PubMed ID: 18998213 [TBL] [Abstract][Full Text] [Related]
20. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Curran WJ Oncology; 2002; 63 Suppl 2():29-38. PubMed ID: 12466642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]